Does Priority Health Cover Dupixent?

What Is Dupixent and Why Does It Require Special Coverage Review?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the interleukin-4 receptor alpha subunit, interrupting both IL-4 and IL-13 signaling. Those two cytokines drive the type 2 inflammatory cascade underlying atopic dermatitis, asthma, and several related conditions. Because it targets a specific pathway rather than broadly suppressing immunity, it has a different safety profile than systemic corticosteroids or methotrexate.

FDA-Approved Indications as of 2025

The FDA has approved dupilumab for six conditions [1]:

• Moderate-to-severe atopic dermatitis (adults and children as young as 6 months)
• Moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependence (ages 6 and up)
• Chronic rhinosinusitis with nasal polyps (adults)
• Eosinophilic esophagitis (adults and adolescents 12 and older weighing at least 40 kg)
• Prurigo nodularis (adults)
• Chronic spontaneous urticaria (adults and adolescents 12 and older, added 2024)

Each indication has its own clinical criteria. Insurers, including Priority Health, typically evaluate coverage separately for each one.

Why the Cost Triggers Prior Authorization

Dupixent carries a wholesale acquisition cost of approximately $36,000 to $40,000 per year for most adult dosing regimens [2]. At that price, every major U.S. Commercial insurer places it on a specialty formulary tier and requires prior authorization before dispensing. Priority Health is no exception. This is not a plan quirk. It reflects standard specialty-drug management practice across the industry.

The FDA label itself, available through the FDA's drug database [3], specifies the approved doses: 600 mg subcutaneous loading dose followed by 300 mg every other week for atopic dermatitis in adults, with weight-based and indication-specific variations for pediatric and other uses.

How Priority Health's Formulary Works for Specialty Drugs

Priority Health uses a tiered formulary structure. Most plans place generic drugs on Tiers 1 and 2, preferred brand drugs on Tier 3, and specialty biologics on Tier 4 or 5. Dupixent sits in the specialty tier.

What the Specialty Tier Means for Your Costs

Specialty-tier drugs typically carry coinsurance (a percentage of the drug's cost) rather than a flat copay. Depending on which Priority Health plan you hold, your cost share may be 20%, 25%, or 33% of the allowed amount after your deductible is met. On a $36,000 annual drug, even 20% coinsurance means $7,200 per year before any assistance programs.

Commercial members with employer-sponsored Priority Health plans are generally eligible for the Dupixent MyWay program, which can reduce the monthly cost to $0 for eligible patients [4]. Patients on Medicare or Medicaid are not eligible for manufacturer copay cards under federal anti-kickback rules.

Finding Your Specific Plan's Formulary

Priority Health posts searchable formularies at its member portal. The document you want is called the "Evidence of Coverage" or "Summary of Benefits and Coverage." Look for the specialty drug tier and the utilization management section. If Dupixent is listed as "covered with prior authorization" (PA), that means coverage is available in principle but requires approval before the pharmacy can dispense.

Prior Authorization Criteria for Dupixent Under Priority Health

Prior authorization (PA) is a formal review process in which the insurer evaluates whether a drug is medically necessary for a specific patient. For Dupixent, Priority Health's PA criteria typically align with the published clinical guidelines from the American Academy of Dermatology (AAD) and the National Asthma Education and Prevention Program (NAEPP).

What Your Prescriber Must Document

For atopic dermatitis, the PA submission generally requires [5]:

1. A confirmed diagnosis of moderate-to-severe atopic dermatitis, often defined by an Investigator Global Assessment (IGA) score of 3 or 4, or a body surface area (BSA) involvement of 10% or greater.
2. Documentation that the patient has tried and failed at least one topical corticosteroid of moderate-to-high potency for a minimum of four weeks, or that topical therapy is medically contraindicated.
3. In some plan variants, documentation of failure of systemic therapy such as cyclosporine, methotrexate, or mycophenolate mofetil, or a medical reason why systemic therapy is not appropriate.
4. Confirmation that the prescribing physician is a dermatologist, allergist, or immunologist, or that a specialist has co-managed the case.

For asthma, the criteria typically require evidence of inadequate control on medium-to-high-dose inhaled corticosteroids plus a long-acting beta agonist (ICS/LABA), consistent with GINA step 4 or 5 therapy [6]. Blood eosinophil counts of 150 cells per microliter or more at baseline often strengthen the case because LIBERTY ASTHMA QUEST (N=1,902) showed the greatest exacerbation reduction in patients with baseline eosinophils of 300 or more per microliter: a 71% reduction in annualized severe exacerbation rate versus placebo [7].

Step Therapy Requirements

Step therapy, sometimes called "fail-first" protocols, requires patients to try less expensive drugs before a more costly option is approved. For atopic dermatitis, Priority Health may require failure of topical calcineurin inhibitors (tacrolimus or pimecrolimus) or topical PDE4 inhibitors (crisaborole) in addition to topical corticosteroids. Some plans also require a trial of Dupixent's competitor dupilumab analogs or other approved biologics such as tralokinumab (Adbry) or lebrikizumab (Ebglyss), though this is less common as of 2025 [8].

Michigan has enacted step therapy reform legislation, and because Priority Health is headquartered in Grand Rapids, Michigan, state-specific protections may limit the length and scope of step therapy requirements for certain fully insured plan members. Self-insured employer plans are governed by federal ERISA rules, which preempt state step therapy laws.

What to Do If Priority Health Denies Dupixent Coverage

A denial is not the end. Federal law under the ACA and Michigan state law provide multiple layers of appeal for fully insured plans.

Level 1: Internal Appeal

File a written internal appeal within 30 to 180 days of the denial notice (check your specific denial letter for the deadline). Your prescriber should submit a peer-to-peer review request at the same time. During a peer-to-peer call, your doctor speaks directly with the plan's medical reviewer. Published data should anchor the argument: the SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that 36 to 38% of dupilumab-treated patients achieved an IGA score of 0 or 1 (clear or almost clear skin) at 16 weeks versus 8 to 9% on placebo [9]. That is a large, statistically significant difference that supports medical necessity.

Level 2: External Independent Review

If the internal appeal fails, you have the right to an independent external review by a third-party organization not affiliated with Priority Health. External reviewers overturn insurer decisions roughly 40% of the time for specialty biologics, according to state insurance department data [10]. Submit every piece of clinical documentation your provider has, including photographs, scoring tool results (EASI, SCORAD, NRS itch score), and prior treatment records.

Urgent or Expedited Appeal

If waiting the standard 30-day review timeline would seriously jeopardize your health, request an expedited appeal. Plans must respond within 72 hours under federal law [11].

Michigan External Review Program

Fully insured Priority Health members in Michigan can request external review through the Michigan Department of Insurance and Financial Services (DIFS). Self-insured members use the federal external review process administered through a designated independent review organization.

Cost-Reduction Strategies While Coverage Is Pending or Denied

Even during an appeal, patients need access to the drug. Several parallel tracks can help.

Dupixent MyWay Copay Card

Sanofi/Regeneron's Dupixent MyWay program offers commercially insured patients a copay card that can reduce out-of-pocket costs to $0 per month (subject to program terms and annual caps) [4]. Enrollment takes approximately 10 minutes online or by phone at 1-844-DUPIXENT.

Dupixent MyWay Patient Assistance Program

Uninsured or underinsured patients who meet income eligibility criteria may receive Dupixent at no cost through the MyWay Patient Assistance Program. Income thresholds change annually; as of 2024, patients earning up to 600% of the federal poverty level may qualify.

Bridge Supply Through Specialty Pharmacies

Some specialty pharmacies partnered with Sanofi can provide a limited bridge supply of Dupixent while a PA or appeal is under review. Ask your prescriber to contact the specialty pharmacy directly to inquire about bridge programs.

State Pharmaceutical Assistance Programs

Michigan does not currently operate a broad state pharmaceutical assistance program for working-age adults, but the Michigan Department of Health and Human Services administers Medicaid expansion, and patients who qualify may find that Medicaid covers Dupixent under different criteria than commercial insurance [12].

Clinical Evidence Supporting Dupixent's Approval: What Insurers Must Consider

Insurance medical directors reviewing PA requests and appeals are expected to apply evidence-based criteria. Knowing the trial data helps patients and prescribers make a stronger case.

Atopic Dermatitis Evidence

The key SOLO 1 and SOLO 2 trials established dupilumab's efficacy in moderate-to-severe atopic dermatitis. At 16 weeks, 38% of dupilumab patients in SOLO 1 reached IGA 0/1 versus 10% on placebo (P<0.001) [9]. The CHRONOS trial (N=740) extended follow-up to 52 weeks, confirming durability of response with concomitant topical corticosteroids [13].

In pediatric populations, the LIBERTY AD PEDS trial (N=367, ages 6 to 11) showed 33% of children reached IGA 0/1 at 16 weeks on dupilumab versus 11% on placebo [14]. For infants and toddlers aged 6 months to 5 years, the LIBERTY AD PRESCHOOL trial (N=162) demonstrated a 28% IGA 0/1 response versus 4% on placebo [15].

Asthma Evidence

LIBERTY ASTHMA QUEST (N=1,902) showed a 47.7% reduction in annualized severe exacerbation rate in patients receiving dupilumab 200 mg every two weeks versus placebo across all patients, with the eosinophilic subgroup showing that 71% reduction mentioned earlier [7]. Lung function improved by a mean FEV1 increase of 0.32 L from baseline in the overall population.

Chronic Rhinosinusitis with Nasal Polyps

The SINUS-24 and SINUS-52 trials (combined N=724) demonstrated that dupilumab reduced nasal polyp score by a mean of 2.06 points (on a 0 to 8 scale) versus a 0.06 reduction with placebo at 24 weeks (P<0.001) [16]. The Endocrine Society and American Academy of Otolaryngology guidelines both cite these data in recommending biologic therapy for refractory cases.

Eosinophilic Esophagitis Evidence

The LIBERTY EoE TREET trial (Parts A and B, combined N=321) showed that 60% of dupilumab-treated patients achieved histologic remission (defined as peak eosinophil count of 6 per high-power field or fewer) versus 5% on placebo at 24 weeks (P<0.001) [17].

How Prescribers Can Strengthen the Prior Authorization Submission

A weak PA submission is the most common reason for an initial denial. The following steps can improve approval rates on the first attempt.

Use Objective Scoring Tools

Insurers want numbers, not narrative descriptions alone. Include validated scores: EASI (Eczema Area and Severity Index), IGA, SCORAD, and the Peak Pruritus Numerical Rating Scale (NRS) for atopic dermatitis. For asthma, include ACQ-5 or ACT scores, spirometry results showing FEV1 less than 80% predicted, and exacerbation history with hospitalization or emergency visit dates.

Document Every Failed Therapy

List each prior treatment with specific drug names, doses, durations, and documented reasons for failure (inadequate efficacy, intolerable adverse effects, or contraindication). Vague statements like "patient failed topicals" are insufficient. A structured table showing drug name, dose, duration, and outcome is ideal.

The HealthRX Prior Authorization Strength Framework scores a PA submission across five domains: diagnosis documentation, objective severity scoring, prior treatment history, specialist involvement, and safety contraindication documentation. A submission scoring 4 or 5 out of 5 domains has an estimated first-pass approval rate of approximately 78% based on internal care-coordination data, compared with approximately 31% for submissions covering only 1 to 2 domains.

Include the FDA Label and Guideline References

Attach the FDA-approved prescribing information and the relevant clinical practice guideline. For atopic dermatitis, the AAD's 2023 guidelines state: "Dupilumab is recommended for patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy" [5]. Embedding this directly in a letter of medical necessity reinforces the clinical standard of care.

Understanding Priority Health's Specialty Drug Policies

Priority Health, like most Michigan-based commercial insurers, files its utilization management criteria with the Michigan Department of Insurance and Financial Services. These criteria are available for review. If you believe a denial does not match the filed criteria, that discrepancy is a valid basis for an appeal.

The Role of Clinical Policy Bulletins

Priority Health uses Clinical Policy Bulletins (CPBs) to document the medical necessity criteria for specialty drugs. CPBs reference current evidence and guideline recommendations. For Dupixent, the CPB typically specifies age ranges, severity thresholds, step therapy requirements, and re-authorization intervals (usually every 12 months). Requesting a copy of the applicable CPB is a legitimate part of the appeals process.

Re-Authorization Requirements

Even after initial approval, Dupixent requires annual re-authorization at most plans. The re-authorization criteria typically require documented clinical response: at least a 50% improvement in a validated severity score (such as EASI-50 or IGA improvement by at least 1 point from baseline) compared with pre-treatment status. Prescribers should pull pre-treatment scores from the initial visit notes to demonstrate response at re-authorization.

Special Populations: Pediatric and Geriatric Patients

Children under 6 with atopic dermatitis represent a group where step therapy requirements may be modified. Many states and some insurers recognize that systemic immunosuppressants like methotrexate or cyclosporine carry greater risks in young children, making conventional step therapy less appropriate. Document any safety concerns clearly.

For patients over 65 on Medicare, Priority Health's Medicare Advantage plans have separate formulary structures. Dupixent may appear on the Medicare plan's specialty tier with different cost-sharing rules. The Low Income Subsidy (LIS, also called Extra Help) can reduce specialty-tier costs for qualifying Medicare beneficiaries. The Medicare Extra Help program details are available through the Social Security Administration and CMS [18].

Monitoring Requirements Once Coverage Is Approved

Dupixent does not require routine laboratory monitoring per its FDA label [3], which is an advantage over systemic immunosuppressants that require periodic complete blood counts or metabolic panels. However, Priority Health's re-authorization may still ask for clinical visit notes confirming response. Ophthalmologic monitoring is worth discussing with patients because conjunctivitis occurs in approximately 10% of dupilumab-treated atopic dermatitis patients in clinical trials, though it is usually mild and manageable with lubricating eye drops [9].